Shyamakant Giri

#251

Chief Executive Officer

Gland Pharma·Healthcare

Age

28y

Exp

Tenure

5/10

Risk

PragmaticOutsiderLarge Cap

🎓 B.Sc. Chemistry · not found

📜 MMM · Jamnalal Bajaj Institute of Management Studies

🏛️ None

Company NSE

CompensationTBP

Personality

Open

Cons

Extr

Agre

Neur

Gland Pharma

Healthcare · Large Cap

High Growth · Performance-Driven

About

Shyamakant Giri is the Chief Executive Officer of Gland Pharma, a Large Cap company in the Healthcare sector with a market cap of ₹28K Cr. A Pragmatic leader with 28 years of experience, he is known for data-driven decision-making and organic builder strategy. Maintains a disciplined, process-oriented approach consistent with the company's complex sterile injectables manufacturing footprint.

FAQ

What is Shyamakant Giri's leadership style?

Shyamakant Giri is classified as a Pragmatic leader. He is data-driven in decision-making, with a shareholder champion motivation and steady-marathon pace of execution.

What is Shyamakant Giri's educational background?

Shyamakant Giri holds a B.Sc. Chemistry from not found and a MMM from Jamnalal Bajaj Institute of Management Studies.

Who is the CEO of Gland Pharma?

Shyamakant Giri is the Chief Executive Officer of Gland Pharma. He has been with the company for 1 years and in the current role for 1 years.

Leadership DNA

ArchetypePragmatic

MotivationShareholder Champion

CrisisSteady Hand

DecisionData-Driven

GrowthOrganic Builder

PeopleNumbers Driven

InnovationFast-Follower

PaceSteady-Marathon

PurposeProfit-Pure

CustomerB2B-Enterprise

EmployerDemanding Machine

BrandTechnical-Expert

FocusOperational Excellence

OrientationDeep Specialist

Leadership Evidence

“Maintains a disciplined, process-oriented approach consistent with the company's complex sterile injectables manufacturing footprint.”

⚡ Crisis●●●●○

Giri has maintained Gland Pharma's focus on operational stability and consistent supply chain execution despite the volatility in the generic injectable market and regulatory oversight.

🎯 Motivation●●●●○

As CEO of a publicly listed entity with significant institutional ownership, his focus remains on maintaining margins and delivering consistent financial performance for investors.

👥 People●●●●●

Giri is widely recognized for his pragmatic, data-driven approach to management, prioritizing operational KPIs and manufacturing efficiency over soft-culture initiatives.

📈 Growth●●●●○

Giri's tenure has focused on expanding Gland Pharma's manufacturing capacity and deepening its core portfolio of complex injectables rather than pursuing aggressive external acquisitions.

💡 Innovation●●●●○

The company specializes in complex generic injectables, focusing on high-quality manufacturing and rapid portfolio expansion through regulatory approvals rather than pioneering new drug discovery.

🏃 Pace●●●●○

The company operates on a methodical, long-term cycle of facility capacity expansion and multi-year regulatory filings in highly regulated markets like the US and Europe.

🌱 Purpose●●●●○

As a B2B pharmaceutical manufacturer, its strategic focus is heavily centered on operational efficiency, global supply chain reliability, and shareholder value, with CSR activities limited to statutory compliance.

🏷️ Brand●●●●●

The company is recognized in the industry for its specialized technical capability in complex sterile injectables and its strong track record of successful USFDA site inspections.

🤝 Customer●●●●●

Gland Pharma operates primarily as a contract manufacturer and B2B supplier of sterile injectables to global pharmaceutical companies and hospital networks.

💼 Employer●●●○○

The nature of sterile pharmaceutical manufacturing requires strict adherence to global regulatory standards (USFDA), resulting in a high-pressure, process-oriented work environment.

📋 Mandate

Navigating complex global regulatory environments while expanding into niche generic injectables requires a leader focused on R&D-driven product innovation.

🏢 Culture●●●○○

Highly professionalized generic manufacturing environment with strict regulatory and KPI compliance common in specialized healthcare firms.